Breast Cancer

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.

During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways.

The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.

Patients with HER2-positive metastatic breast cancer experienced promising preliminary safety and efficacy with trastuzumab deruxtecan alone and in combination with pertuzumab.

Improvements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.

Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.

Long-term findings from the phase 2 GeparOLA trial indicate that olaparib plus paclitaxel and carboplatin did not result in further benefit vs paclitaxel, and carboplatin for patients with HER2-negative, homologous recombination–deficient early breast cancer.

Robert Mutter, MD, of Mayo Clinic says that proton postmastectomy radiation therapy allows for excellent tissue sparing in the management of breast cancer.

Patients with multiple ipsilateral breast cancer might benefit from having a preoperative MRI before proceeding with breast conservation therapy, according to Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota.

Results from the phase 3 STIC CTC trial found an improved overall survival when circulating tumor cells were used as a guide in combination with chemotherapy or endocrine therapy in patients with hormone receptor–positive/HER2-negative breast cancer.

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.

Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.

ARV-471 monetherapy showed clinical benefit in an expansion cohort of patients with locally advanced or metastatic breast cancer, according to data from the VERITAC trial.

Treatment with a range of camizestrant monotherapy doses resulted in a survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

Results from the phase 3 CAPItello-291 trial indicated that the combination of capivasertib plus fulvestrant produced improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.

Heather McArthur, MD, presents the case of a 69-year-old woman with stage II HER2+ mBC for discussion.

Data from the phase 2 TRIO-US B-12 TALENT trial indicate that fam-trastuzumab deruxtecan-nkxi in the neoadjuvant setting with or without endocrine therapy could be beneficial for patients with hormone receptor–positive, HER2-low breast cancer.

Yoga and conventional exercises also demonstrated long-term improvement in quality of life during treatment for non-metastatic breast cancer, according to results presented at the 2022 San Antonio Breast Cancer Symposium.

Experts believe that use of the Breast Cancer Index test in patients with early-stage, hormone receptor–positive breast cancer who are undergoing treatment with endocrine therapy may help to identify those who could be good candidates for the addition of ovarian function suppression.